Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC.
Urologic Cancers News
UROLOGIC CANCER ADVISOR
Urologic Cancers News
Model Proposed to Guide Use of Adjuvant Radiation Therapy for MIBC
Investigators found that the odds of locoregional recurrence of muscle-invasive bladder cancer following radical cystectomy depend on disease risk category.
Algorithm Proposed to Expand Cisplatin Eligibility for MIBC
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Imfinzi Indication for Urothelial Carcinoma Withdrawn
Under the accelerated approval program, if a confirmatory trial does not show clinical benefit, the FDA can take steps to remove the drug or indication.
AstraZeneca Voluntarily Withdraws Imfinzi Indication in Locally Advanced or Metastatic Bladder Cancer
AstraZeneca has voluntarily withdrawn durvalumab’s (Imfinzi’s) indication for adults with locally advanced or metastatic bladder cancer.
ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF Resistance
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
COVID-19 Adversely Affecting Patients With Genitourinary Cancers
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic.
Vicineum gets Priority Review for High-Risk, BCG-Unresponsive NMIBC
Vicineum has been awarded a priority review for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Tumor Mutational Burden, Immune-Related Adverse Events in Metastatic Urothelial Cancer
Researchers analyzed data from patients with metastatic urothelial cancer to determine whether tumor mutation burden was associated with immune-related AEs among patients treated with immune checkpoint inhibitors.
Demographic Factors With Stage at Diagnosis and Use of Treatment in Bladder Cancer
Researchers sought to identify social disparities in diagnosis and treatment among patients with bladder cancer.
Palliative Care Use in Advanced Renal Cell Carcinoma Linked to Socioeconomic Groups
Researchers sought to determine accessibility and use of palliative care among patients with advanced renal cell carcinoma.
Bladder Pressure May Influence Intravesical Drug Delivery
Using porcine bladders, researchers investigated whether bladder pressure affects the extent to which gemcitabine penetrates the bladder wall with this treatment modality.
Oral HIF-2α Inhibitor Belzutifan Upholds Clinical Activity in RCC
Todd Bauer, MD, presents updated data from a phase 1/2 study of the oral hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan.
Sexual Orientation May Influence Choice to Pursue Screening for ‘Gender-Specific’ Cancers
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
Race Reporting in GU Cancers Indicates Relative Overrepresentation of White Individuals
Lythgoe et al studied patterns of race reporting in genitourinary (GU) cancer trials.
Bone-Targeted Therapies and Incidence of Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.
Effect of Hypertension History on Outcomes in Patients With Metastatic Renal Cell Carcinoma
A retrospective analysis sought to determine the effect of hypertension on overall survival, response, and progression-free survival in patients with mRCC.
NLR Rise May Predict Mortality, Treatment Failure Risks in mRCC
A rise in neutrophil-to-lymphocyte ratio of 3 or more after 2 months of therapy is associated with an increased risk for death in less than 1 year and treatment failure in less than 6 months, according to investigators.
Radiation Therapy Increases Survival in Metastatic Urothelial Carcinoma
Patients with metastatic urothelial carcinoma have significantly longer overall survival when treated with a combination of radiotherapy and chemotherapy compared with chemotherapy alone, a study found.
Study Identifies Risk Factors for Urethral Recurrence After Radical Cystectomy
Study findings support surveillance for urethral recurrence after radical cystectomy.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
